Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
HLA DR/DP Antibody (Bra-14), PE/Cy5.5, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP248006PECY55
Description
HLA DR/DP Monoclonal specifically detects HLA DR/DP in Human samples. It is validated for Flow Cytometry.Specifications
HLA DR/DP | |
Monoclonal | |
PE-Cyanine5.5 | |
PBS with 0.05% Sodium Azide | |
HLA-DRA | |
Human REH cells | |
0.1 mL | |
Primary | |
Reacts with a common epitope of human major histocompatibility (MHC) class II antigens, HLA-DR and DP. Human MHC class II antigens are transmembrane glycoproteins composed of an chain (36kDa) and a chain (27kDa). They are expressed primarily on antigen presenting cells such as B lymphocytes, monocytes, macrophages, and thymic epithelial cells and are also present on activated T lymphocytes. Human MHC class II genes are located in the HLA-D region that encodes at least six and ten chain genes. Three loci, DR, DQ and DP, encode the major expressed products of the human class II region. The human MHC class II molecules bind intracellularly processed peptides and present them to T-helper cells. They, therefore, have a critical role in the initiation of the immune response. It has been shown that some autoimmune diseases are associated with certain class II alleles. | |
Store at 4°C in the dark. Do not freeze. |
Flow Cytometry | |
Bra-14 | |
Flow Cytometry | |
FLJ51114, histocompatibility antigen HLA-DR alpha, HLA class II histocompatibility antigen, DR alpha chain, HLA-DRA1, major histocompatibility complex, class II, DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA, MLRW | |
Mouse | |
Protein A or G purified | |
Adaptive Immunity, Cell Biology, Diabetes Research, Immunology | |
3122.0 | |
Human | |
IgG3 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction